粉样蛋白-β但不是tau的积累与纵向认知衰退密切相关
Wenwen Wang1, Jiani Huang2, Shuangjie Qian2
1The Center of Traditional Chinese Medicine, The Second Affiliated Hospital, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
CNS neuroscience & therapeutics
|July 16, 2024
概括
粉样蛋白-β (Aβ) PET扫描,但不仅仅是tau病理,可以独立预测阿尔茨海默病 (AD) 的认知衰退. 这一发现有助于区分AD连续体中的疾病进展标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物医学研究的研究.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块和团.
- 了解Aβ和tau对认知衰退的独立贡献对于预测AD进展至关重要.
研究的目的:
- 调查Aβ和tau积累是否独立地预测AD连续体中个体的未来认知衰退.
- 评估Aβ-PET和CSFtau对痴呆症进展的预测能力.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 数据库的数据.
- 包括1272名具有基线Aβ-PET和CSF tau数据的参与者.
- 分析了777名参与者的认知衰退,并进行了随访.
主要成果:
- 无论是Aβ-PET还是CSF都与认知能力下降和痴呆症进展有关.
- Aβ-PET (A+T-) 独立预测认知衰退 (ADAS-13,ADNI-MEM,MMSE) 比tau (A-T+) 更好.
- Aβ病理,特别是在APOE ε4载体中,与记忆力下降相关,尽管在考虑APOE ε4状态时,ADNI-MEM领域的相关性较小.
结论:
- 单独的Aβ-PET (A+T-) 是纵向认知衰退和痴呆症进展的可靠独立预测指标.
- 单独的积 (A-T+) 作为认知恶化的独立预测因子是不够的.
- 比tau水平,Aβ-PET SUVR水平与葡萄糖低代谢有更强的相关性.
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:30Cognitive Development During Adulthood
78
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
78
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172